Skip to main content

According to the new outcomes from an NCI-sponsored Children’s Oncology Group (COG) clinical trial, A combination of Atriance/Arranon (nelarabine) and standard chemo led to the highest survival rates seen to date in children and young adults with T-ALL. 

The conducted trial (COG) was the largest-ever clinical trial for those with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL).

Four years after initiating treatment, among T-ALL patients who had a moderate or high risk of their disease returning, 89% of those who received the medicine, nelarabine in addition to standard chemotherapy, had no signs or symptoms of leukemia in comparison to 83% of those who received chemo alone.

Outcomes from NCT00408005/COG AALL0434 Phase-3 Trial:

The NCT00408005/COG AALL0434 trial enrolled a total of 1,895 patients, aged 1 to 30 years, with newly diagnosed T-cell cancers. Most patients in the trial (94%) had T-ALL, and the remaining had T-LL.

Participants were treated with the COG-augmented Berlin-Frankfurt-Munster chemotherapy (standard chemotherapy regimen), with either high-dose methotrexate or gradually increasing methotrexate doses. Those with low or high risk for disease recurrence were then randomly assigned to take Atriance or not. Of the T-cell acute lymphoblastic leukemia patients, 90.2% still survived after 4 years, and 84.3% were without cancer.

For those who received Atriance/Arranon, 88.9% remained cancer-free at least 4 years after initiating treatment in comparison to only 83.3 percent of the low- to high-risk patients who did not receive the medicine Atriance.

However, Atriance did not enhance the outcomes of T-cell lymphoblastic lymphoma patients, 85% of whom were cancer-free at 4 years in comparison to 89% of the control patients.

Atriance was beneficial for patients with T-ALL who took escalating methotrexate doses, 92.2% of whom were cancer-free at 4 years, in comparison to 86.2% in the high-dose methotrexate population.

A total of 43 patients did not reach disease remission early in their treatment phase and were given high-dose methotrexate plus Atriance. More than half (54.8%) of them lived 4 years without signs of cancer. This is a significant enhancement because historically, only around 20% of patients with T-ALL who do not reach disease remission live another 3 years.


Nitin Goswami

Nitin Goswami joined us as an Editor in 2020. He covers all the updates in the field of Pharmaceutical, Business Healthcare, Health News, Medical News, and Pharma News.

Leave a Reply

Close Menu